Aktuelle Leitlinien der axialen Spondyloarthritis für Praxis und Klinik

Iuliia Kononenko; David Kiefer; Xenofon Baraliakos; Uta Kiltz

doi:10.1055/a-2154-0476

Arthritis und Rheuma, Table of Contents

Arthritis und Rheuma 2023; 43(05): 307-314
DOI: 10.1055/a-2154-0476

Schwerpunkt

Aktuelle Leitlinien der axialen Spondyloarthritis für Praxis und Klinik

Authors

Iuliia Kononenko

¹Ruhr-Universität Bochum und Rheumazentrum Ruhrgebiet, Herne
David Kiefer

¹Ruhr-Universität Bochum und Rheumazentrum Ruhrgebiet, Herne
Xenofon Baraliakos

¹Ruhr-Universität Bochum und Rheumazentrum Ruhrgebiet, Herne
Uta Kiltz

¹Ruhr-Universität Bochum und Rheumazentrum Ruhrgebiet, Herne

Abstract

ZUSAMMENFASSUNG

Die axiale Spondyloarthritis (axSpA) ist eine entzündlich-rheumatische Erkrankung des Achsenskeletts, die vor allem durch chronische Rückenschmerzen gekennzeichnet ist. Im Verlauf der Erkrankung kann es zu Knochenneubildungen am Achsenskelett kommen. Internationale und nationale Leitlinien zielen darauf ab, die Diagnose einer axSpA kurz nach Symptombeginn zu stellen und eine effektive Therapie einzuleiten. Bei der Diagnosestellung spielt insbesondere die Bildgebung eine wichtige Rolle. Während das Röntgen und die Computertomografie (CT) strukturelle Läsionen gut darstellen können, ermöglicht die Magnetresonanztomografie (MRT) die Darstellung von entzündlichen und strukturellen Veränderungen. Die Behandlung von Patienten mit axSpA zeichnet sich durch eine Kombination aus nichtpharmakologischen und pharmakologischen Maßnahmen aus. Neben regelmäßiger körperlicher Aktivität können unterschiedliche Medikamentenklassen wie nichtsteroidale Antirheumatika (NSAR) und Biologika (biologic Disease-Modifying Antirheumatic Drugs, bDMARD) sowie targeted-synthetic DMARD (tsDMARD) verordnet werden. Im Laufe der Erkrankung können invasive Maßnahmen wie Injektionen oder Operationen in Frage kommen.

Schlüsselwörter

Axiale Spondyloarthritis - Bildgebung - MRT - Therapie

Full Text

References

Literatur
1 Kiltz U, Braun J. DGRh, et al Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019: Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften und weiterer Organisationen [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew‘s disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations]. Z Rheumatol 2019; 78: 3-64
2 Ramiro S, Nikiphorou E, Sepriano A. et al ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023; 82: 19-34
3 Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 390: 73-84
4 Regierer AC, Weiß A, Baraliakos X. et al [RABBIT-SpA: a new disease register for axial spondyloarthritis and psoriatic arthritis]. Z Rheumatol 2020; 79: 135-142
5 Zhao SS, Pittam B, Harrison NL. et al Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology 2023; 60: 1620-1628
6 Benavent D, Capelusnik D, Ramiro S. et al Looking through the window of opportunity in axial spondyloarthritis?. Jt bone spine 2023; 90: 105603
7 de Winter JJ, van Mens LJ, van der Heijde D. et al Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther 2016; 18: 196
8 López-Medina C, Molto A, Sieper J. et al Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open 2021; 07: e001450
9 Stolwijk C, van Tubergen A, Castillo-Ortiz JD. et al Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 65-73
10 Rudwaleit M, Haibel H, Baraliakos X. et al The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009; 60: 717-727
11 Mielants H, Veys EM, Cuvelier C. et al The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995; 22: 2279-2284
12 Karmacharya P, Crowson CS, Poudel D. et al Comorbidity Clusters in Ankylosing Spondylitis and Their Association with Disease Activity and Functional Impairment: Data from the PSOAS Cohort. Arthritis Rheumatol 2022: 74
13 Österreichische Gesellschaft für Rheumatologie und Rehabilitation. ASPAT (Austrian Spondyloarthritis task Force). Leitfaden „Axiale Spondyloarthritis“ (2019). Im Internet. www.rheumatologie.at/storage/app/media/pdf/2019_11_Leitfaden_axSpA_interaktiv_der_ASPAT.pdf Stand: 25.11.2029
14 Braun J, Bollow M, Remlinger G. et al Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67
15 Costantino F, Talpin A, Said-Nahal R. et al Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort. Ann Rheum Dis 2015; 74: 689-693
16 Baraliakos X, Listing J, Rudwaleit M. et al Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Annals of the rheumatic diseases 2007; 66: 910-915
17 Rudwaleit M, van der Heijde D, Landewé R. et al The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Annals of the rheumatic diseases 2009; 68: 777-783
18 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and rheumatism 1984; 27: 361-368
19 Baraliakos X, Richter A, Feldmann D. et al Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged. Ann Rheum Dis 2020; 79: 186-192
20 Lambert RG, Bakker PA, van der Heijde D. et al Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Annals of the rheumatic diseases 2016; 75: 1958-1963
21 Diekhoff T, Hermann KG, Greese J. et al Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. Ann Rheum Dis 2017; 76: 1502-1508
22 Rennie WJ, Dhillon SS, Conner-Spady B. et al Magnetic resonance imaging assessment of spinal inflammation in ankylosing spondylitis: standard clinical protocols may omit inflammatory lesions in thoracic vertebrae. Arthritis Rheum 2009; 61: 1187-1193
23 Rudwaleit M, Schwarzlose S, Hilgert ES. et al MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Annals of the rheumatic diseases 2008; 67: 1276-1281
24 Baraliakos X, Braun J. Bildgebung bei Patienten mit axialer Spondyloarthritis mit Fokus auf die Knochenneubildung [Imaging in patients with axial spondylarthritis with focus on new bone formation]. Z Rheumatol 2020; 79: 33-39
25 Lukas C, Landewé R, Sieper J. et al Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Annals of the rheumatic diseases 2009; 68: 18-24
26 Gwinnutt JM, Wieczorek M, Balanescu A. et al 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis 2023; 82: 48-56
27 Reiner M, Niermann C, Jekauc D. et al Long-term health benefits of physical activity – a systematic review of longitudinal studies. BMC public health 2013; 13: 813
28 Liang H, Zhang H, Ji H. et al Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis. Clin Rheumatol 2015; 34: 1737-1744
29 O’Dwyer T, O’Shea F, Wilson F. Exercise therapy for spondyloarthritis: a systematic review. Rheumatol Int 2014; 34: 887-902
30 Song IH, Poddubnyy DA, Rudwaleit M. et al Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008; 58: 929-938
31 Baraliakos X, Kiltz U, Peters S. et al Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford) 2017; 56: 95-102
32 van der Heijde D, Deodhar A, Baraliakos X. et al Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis 2023; 82: 515-526
33 Deodhar A, Sliwinska-Stanczyk P, Xu H. et al Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the rheumatic diseases 2021; 80: 1004-1013
34 Deodhar A, Van den Bosch F, Poddubnyy D. et al Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2022; 400: 369-379
35 van der Heijde D, Song IH, Pangan AL. et al Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019; 394: 2108-2117
36 Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E. et al Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD open 2017; 03: e000524
37 Micheroli R, Tellenbach C, Scherer A. et al Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Annals of the rheumatic diseases 2020; 79: 1203-1209
38 Torgutalp M, Rios Rodriguez V, Proft F. et al Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort. Arthritis Rheumatol 2022; 74: 1515-1523
39 Molnar C, Scherer A, Baraliakos X. et al TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2018; 77: 63-69
40 Baraliakos X, Østergaard M, Poddubnyy D. et al Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study. Arthritis Rheumatol 2023: 74
41 Baraliakos X, Listing J, Brandt J. et al Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005; 07: R439-R444
42 Webers C, Ortolan A, Sepriano A. et al Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis 2023; 82: 130-141
43 Lee SH, Lee GW, Seol YJ. et al Comparison of Outcomes of Total Hip Arthroplasty between Patients with Ankylosing Spondylitis and Avascular Necrosis of the Femoral Head. Clinics in orthopedic surgery 2017; 09: 263-269
44 Wang Y, Xue C, Song K. et al Comparison of loss of correction between PSO and VCD technique in treating thoracolumbar kyphosis secondary to ankylosing spondylitis, a minimum 2 years follow-up. Journal of orthopaedic surgery and research 2019; 14: 137